FAQ

ARN-509

Known as: Androgen Receptor Antagonist ARN-509 
A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2018
0246820102018

Related topics

Related topics

1 relation

Broader (1)

Thiohydantoins

Related mentions per year

Related mentions per year

1947-2018
19401960198020002020
ARN-509
Thiohydantoins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.
Purpose: To evaluate the efficacy of apalutamide before or after treatment with abiraterone acetate and prednisone (AAP) in… (More)
Is this relevant?
2016
2016
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
BACKGROUND Apalutamide is a potent androgen receptor (AR) antagonist that targets the AR ligand-binding domain and prevents AR… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2015
2015
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
Activation of androgen receptor (AR) is crucial for prostate cancer growth. Remarkably, also castration-resistant prostate cancer… (More)
Is this relevant?
2014
2014
Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
Androgens are key factors involved in the development and progression of prostate cancer (PCa), and PCa growth can be suppressed… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.
UNLABELLED Despite the impressive clinical activity of the second-generation antiandrogens enzalutamide and ARN-509 in patients… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.
PURPOSE ARN-509 is a novel androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (CRPC… (More)
Is this relevant?
2013
2013
ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC).
7 Background: ARN-509 is a novel second-generation anti-androgen that binds directly to the ligand-binding domain of the androgen… (More)
Is this relevant?
2013
2013
ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC).
48 Background: ARN-509 is a novel second-generation anti-androgen that binds directly to the ligand-binding domain of the… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
ARN-509: a novel antiandrogen for prostate cancer treatment.
Continued reliance on the androgen receptor (AR) is now understood as a core mechanism in castration-resistant prostate cancer… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Development of anti-androgen ARN-509 1 ARN-509: a novel anti-androgen for prostate cancer treatment
Nicola J. Clegg, John Wongvipat, Jim Joseph, Chris Tran, Samedy Ouk, Anna Dilhas, Yu Chen, Kate Grillot, Eric D. Bischoff , Ling… (More)
  • table 1
  • figure 1
Is this relevant?